Outcomes for patients with oropharyngeal cancer are determined by their tumor characteristics and associated demographics. The role of human papilloma virus-related disease for prognosis and outcomes with chemoradiotherapy is being more clearly defined. EGFR inhibitors are used in conjunction with radiotherapy, and the importance of optimizing radiation quality and minimizing toxicity is the focus of ongoing studies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer
Cancers of the Head & Neck Open Access 11 July 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24–35 (2010).
Rischin, D. et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J. Clin. Oncol. 28, 4142–4148 (2010).
Peters, L. J. et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J. Clin. Oncol. 28, 2996–3001 (2010).
Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567–578 (2006).
Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21–28 (2010).
Cohen, E. E. et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 28, 3336–3343 (2010).
Salama, J. K. et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann. Oncol. 19, 1787–1794 (2008).
Feng, F. Y. et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J. Clin. Oncol. 28, 2732–2738 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B. E. Brockstein has worked as a consultant for Exelixis, Novartis, and Oncolytics, and is on the speakers bureau (honoraria) for Novartis. E. E. Vokes has worked as a consultant for Bristol-Myers Squibb, Eli Lilly, and ImClone.
Rights and permissions
About this article
Cite this article
Brockstein, B., Vokes, E. Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol 8, 72–74 (2011). https://doi.org/10.1038/nrclinonc.2010.226
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.226
This article is cited by
-
Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer
Cancers of the Head & Neck (2016)
-
A river model to map convergent cancer evolution and guide therapy in RCC
Nature Reviews Urology (2015)
-
Gene Expression Characterization of HPV Positive Head and Neck Cancer to Predict Response to Chemoradiation
Head and Neck Pathology (2015)
